COHR vs IPGP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: COHR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COHR and IPGP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COHR and IPGP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Coherent Corp, formerly II-VI and now trading as COHR on the NYSE, makes lasers, optical components, and high-speed transceivers used in AI data centers, telecom networks, industrial manufacturing, and semiconductors. Its largest and fastest-growing segment is Datacenter & Communications, which supplies the 800G and emerging 1.6T optical transceivers that connect GPUs and switches inside AI clusters, alongside a smaller Industrial segment covering lasers and materials.

Full COHR guide

IPG Photonics designs and builds fiber lasers, amplifiers and complete laser systems, and it is unusually vertically integrated: it makes its own semiconductor diodes, specialty fiber and optical components rather than buying them. That integration is what let it undercut older laser technologies on cost and reliability two decades ago. Revenue is reported in two segments. Industrial Solutions, about 85% of sales, supplies lasers that fabricators, carmakers, battery makers and general manufacturers use to cut, weld, clean, mark and 3D-print metal. Advanced Solutions covers medical, micromachining, scientific and defense work, including the CROSSBOW counter-drone laser system sold under the IPG Defense name. The company earns money mainly on equipment sales to machine builders and end users, plus a smaller stream of service, parts and accessories.

Full IPGP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COHR drivers: AI datacom transceiver demand; Transition to 1.6T optics.
• IPGP drivers: Industrial demand recovery; Emerging growth products.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: COHR has traded at a high earnings multiple (about 57 times trailing earnings even after the pullback), so any slowdown in AI capital spending or a demand air pocket can hit the stock hard, as the October 2026 sell-off on AI funding worries showed. For IPGP, the biggest risk is the industrial capital-spending cycle.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COHR if you believe its drivers more; IPGP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COHR and IPGP guides.

COHR. The gap between a trailing P/E near 57 and a forward multiple near 17 shows how much earnings growth the market and analysts are counting on, with consensus calling for EPS to roughly double over two years. The stock's 25% fall in the month to October 16, 2026 cut the market value from around $70 billion in the summer to about $46.5 billion. The next test is the fiscal first quarter report on November 4, 2026, where consensus expects about $2.3 billion of revenue and $1.96 of EPS.

IPGP. Analysts expect about $1.12 billion of revenue and roughly $1.86 of adjusted EPS for 2026, rising to about $1.22 billion and $2.31 in 2027. At about $71 a share that is under 3 times sales and roughly 31 times forward earnings, while the trailing GAAP P/E is above 100 because reported profit is thin. Cash and short-term investments cover close to 30% of the market value. The valuation therefore rests on margins recovering toward historical levels, not on current GAAP earnings. The stock sits near its 52-week low of about $69 after peaking near $156.

Headline figures (approximate, October 2026): COHR shows revenue (fy2026, ttm) ~$7.12B, +34% YoY in Q4, q4 fy2026 revenue ~$2.05B (top of $1.91B-$2.05B guidance), q4 fy2026 non-gaap eps ~$1.74 vs ~$1.62 consensus, net income (ttm) ~$770M, ~11% net margin; IPGP shows revenue (ttm) ~$1.07 billion, q2 2026 revenue ~$278.6 million (up ~11% YoY), q2 2026 eps $0.12 GAAP, ~$0.58 adjusted, gross margin (q2 2026) ~40.4% GAAP (37.3% a year earlier).

COHR and IPGP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COHR and IPGP exposure against your real portfolio. It is not an investment adviser.